Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascletis Pharma, Inc. ( (HK:1672) ) has shared an update.
Ascletis Pharma Inc. has completed enrollment for its U.S. Phase IIa study of ASC30, a small molecule oral GLP-1R agonist designed for obesity treatment. This milestone highlights the rapid enrollment of 125 participants, indicating a significant unmet need for obesity treatments. The study aims to evaluate the efficacy, safety, and tolerability of ASC30, with topline data expected in the fourth quarter of 2025. ASC30, developed in-house, offers potential once-daily oral and once-monthly subcutaneous dosing options, which could enhance the company’s positioning in the obesity treatment market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company specializes in small molecule drugs and has a market focus on obesity treatment with its investigational GLP-1R agonist, ASC30.
Average Trading Volume: 5,720,572
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.18B
For an in-depth examination of 1672 stock, go to TipRanks’ Overview page.